These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.
Novartis (NVS) Upgraded to Buy: Here's Why
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Novartis (NVS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Swiss competition authority closes Novartis probe without consequences
Switzerland's COMCO competition commission terminated an investigation against Novartis into possibly using blocking patents, without consequences, it said on Thursday.
NVS or LLY: Which Is the Better Value Stock Right Now?
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?
Novartis: Value Continues To Build With Double-Digit Percentage Growth Products
Kesimpta continues to do well as a self-administered drug for the treatment of patients with relapsing multiple sclerosis; Q2 2024 sales of $799 million, which is growth of 65% YOY. Pluvicto, as a treatment option for patients with metastatic castration-resistant prostate cancer, has been able to generate Q2 of 2024 sales of $345 million which is growth of 44% YOY. With the FDA accepting the regulatory submission of Scemblix, there is a chance to expand the label to target 1st-line chronic myeloid leukemia patients.
Novartis: Best Performing Big Pharma Of Past 6 Months Still Looks A Solid Long-Term Bet
Novartis shares have risen over 20% in the past 6 months, making it the best-performing global pharmaceutical stock, with strong profitability and manageable debt. Despite some declining revenues from established brands, Novartis' pipeline and recent performance suggest continued growth, with double-digit revenue and income growth expected in 2024. The company lacks a "mega-blockbuster" drug but has a solid portfolio and potential for strategic acquisitions to enhance its pipeline.
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs. CEO Vas Narasimhan said the company was researching treatments that deal with the secondary effects of weight loss, but that it does not plan to compete directly with Novo Nordisk and Eli Lilly.
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Vas Narasimhan, CEO of Novartis, says the pharmaceutical company does not plan to follow competitors in entering into the weight loss drugs market.
